Study With Wee-1 Inhibitor MK-1775 and Carboplatin to Treat p53 Mutated Refractory and Resistant Ovarian Cancer (M10MKO)
This study is currently recruiting participants.
Verified September 2012 by The Netherlands Cancer Institute
Sponsor:
The Netherlands Cancer Institute
Collaborator:
Merck
Information provided by (Responsible Party):
Otilia Dalesio, The Netherlands Cancer Institute
ClinicalTrials.gov Identifier:
NCT01164995
First received: July 9, 2010
Last updated: September 11, 2012
Last verified: September 2012
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
No Study Results Posted on ClinicalTrials.gov for this Study
| Study Status: | This study is currently recruiting participants. |
|---|---|
| Estimated Study Completion Date: | September 2013 |
| Estimated Primary Completion Date: | July 2013 (Final data collection date for primary outcome measure) |